Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Abstract

Among 1402 participants from 3 selected cohorts, plasma P-tau217 discriminated AD from other neurodegenerative diseases, with significantly higher accuracy than established plasma- and MRI-based biomarkers, and its performance was not significantly different from key CSF- or PET-based measures. Further research is needed to optimize the assay, validate the findings in unselected and diverse populations, and determine its potential role in clinical care.

Keywords

Affiliated Institutions

• Massachusetts General Hospital US
• University of Gothenburg SE
• Harvard University US
• Arizona State University US
• Universidad de Antioquia CO
• National Hospital for Neurology and Neurosurgery GB
• Skåne University Hospital SE
• Banner Alzheimer’s Institute
• Translational Genomics Research Institute US
• Sahlgrenska University Hospital SE
• University Medical Center Hamburg-Eppendorf DE
• University College London GB
• Alzheimer's Association US
• UK Dementia Research Institute GB
• Universität Hamburg DE
• Banner Sun Health Research Institute US
• Lund University SE
• Eli Lilly (United States) US

Related Publications